Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies

James M. Bogenberger, Devora Delman, Nanna Hansen, Riccardo Valdez, Veena Fauble, Ruben A. Mesa, Raoul Tibes

Research output: Contribution to journalArticle

37 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)226-229
Number of pages4
JournalLeukemia and Lymphoma
Volume56
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Heterocyclic Bridged Bicyclo Compounds
Proto-Oncogene Proteins c-bcl-2
Biphenyl Compounds
Piperazines
Azacitidine
Nitrophenols
Myeloid Leukemia
Sulfonamides
Tumor Cell Line
Antineoplastic Agents
Neoplasms
ABT-737
4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Bogenberger, J. M., Delman, D., Hansen, N., Valdez, R., Fauble, V., Mesa, R. A., & Tibes, R. (2015). Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leukemia and Lymphoma, 56(1), 226-229. https://doi.org/10.3109/10428194.2014.910657

Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. / Bogenberger, James M.; Delman, Devora; Hansen, Nanna; Valdez, Riccardo; Fauble, Veena; Mesa, Ruben A.; Tibes, Raoul.

In: Leukemia and Lymphoma, Vol. 56, No. 1, 01.01.2015, p. 226-229.

Research output: Contribution to journalArticle

Bogenberger, JM, Delman, D, Hansen, N, Valdez, R, Fauble, V, Mesa, RA & Tibes, R 2015, 'Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies', Leukemia and Lymphoma, vol. 56, no. 1, pp. 226-229. https://doi.org/10.3109/10428194.2014.910657
Bogenberger, James M. ; Delman, Devora ; Hansen, Nanna ; Valdez, Riccardo ; Fauble, Veena ; Mesa, Ruben A. ; Tibes, Raoul. / Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 1. pp. 226-229.
@article{467524e2cb3b4529a0e72f923b9f7dc8,
title = "Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies",
author = "Bogenberger, {James M.} and Devora Delman and Nanna Hansen and Riccardo Valdez and Veena Fauble and Mesa, {Ruben A.} and Raoul Tibes",
year = "2015",
month = "1",
day = "1",
doi = "10.3109/10428194.2014.910657",
language = "English (US)",
volume = "56",
pages = "226--229",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies

AU - Bogenberger, James M.

AU - Delman, Devora

AU - Hansen, Nanna

AU - Valdez, Riccardo

AU - Fauble, Veena

AU - Mesa, Ruben A.

AU - Tibes, Raoul

PY - 2015/1/1

Y1 - 2015/1/1

UR - http://www.scopus.com/inward/record.url?scp=84922360342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922360342&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.910657

DO - 10.3109/10428194.2014.910657

M3 - Article

C2 - 24707940

AN - SCOPUS:84922360342

VL - 56

SP - 226

EP - 229

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -